Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press161010.17650/1726-9776-2022-18-2-226-228RESOLUTIONРЕЗОЛЮЦИЯResolution of the expert council “Modern options for the treatment of urothelial cancer”Резолюция по итогам совета экспертов на тему «Современные возможности лечения уротелиального рака»160820221822262281508202215082022https://oncourology.abvpress.ru/oncur/article/view/1610
.
.
SEER Cancer Stat Facts: Bladder Cancer. National Cancer Institute. Bethesda, MD. Available at: https://seer.cancer.gov/statfacts/html/urinb.html.Petkau V., Zukov R., Alekseeva G., Mazhbich M. The association of access to systemic therapy and overall survival in metastatic bladder cancer in Russia: an analysis of URRU register. J Clin Oncol 2021;39(28_suppl):88. DOI: 10.1200/JCO.2020.39.28_suppl.88Valderrama B.P., Castellano D., Marín Á.P. et al. Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with carboplatin/gemcitabine (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy (“INDUCOMAIN”). ESMO 2020 virtual congress. Ann Oncol 2020;31.Valderrama B.P., Castellano D., Marín Á.P. et al. Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with carboplatin/ gemcitabine (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy (“INDUCOMAIN”). ESMO 2020 virtual congress. Ann Oncol 2020;31.NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. V1.2022. Available at: https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf.Powles T., Bellmunt J., Comperat E. et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and followup. Ann Oncol 2022;33(3):244–58. DOI: 10.1016/j.annonc.2021.11.012Ministry of Health of Russia. Clinical Guidelines “Urotelial carcinoma”. Available at: https://cr.minzdrav.gov.ru/recomend/526_1. (In Russ.).Министерство здравоохранения Российской Федерации. Клинические рекомендации «Уротелиальная карцинома». Доступно по: https://cr.minzdrav.gov.ru/recomend/526_1.Dogliotti L., Cartenì G., Siena S. et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007;52(1):134–41. DOI: 10.1016/j.eururo.2006.12.029De Santis M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30(2):191–9. DOI: 10.1200/JCO.2011.37.3571De Santis M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II – results of EORTC study 30986. J Clin Oncol 2009;27(33):5634–9. DOI: 10.1200/JCO.2008.21.4924Gupta S., Sonpavde G., Grivas P. et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). ASCO 2019, suppl 451. Available at: https://doi.org/10.1200/JCO.2019.37.7_suppl.451.Powles T. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Eng J Med 2020;383(13):1218–30.Grivas P. Pd10-02 avelumab first-line maintenance for advanced urothelial carcinoma: long-term follow-up results from the Javelin Bladder 100 trial. J Urol 2022;207 (Suppl 5):e183.Powles T., Voog E., Park S.H., Caserta C. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up results from the Javelin Bladder 100 trial. J Clin Oncol 2022;40(6_suppl):487. DOI: 10.1200/JCO.2022.40.6_suppl.487Clinical trials for 2021-001975-17. Available at: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001975-17.